Patents by Inventor Colin C. Collins

Colin C. Collins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
    Patent number: 9790500
    Abstract: Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 17, 2017
    Inventors: Yuzhuo Wang, Hui Xue, Sze Ue Luk, Peter Wilhelm Gout, Martin E. Gleave, Colin C. Collins
  • DUAL TARGETING ANTISENSE OLIGONUCLEOTIDES AS APOPTOTIC INHIBTOR THERAPEUTIC COMPOSTIONS AND METHODS FOR THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20170015997
    Abstract: Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC).
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: Yuzhuo Wang, Hui Xue, Sze Ue Luk, Peter Wilhelm Gout, Martin E. Gleave, Colin C. Collins
  • Biomarkers for prostate cancer metastasis
    Patent number: 7482123
    Abstract: The present invention provides genomic markers for determining the predisposition of prostate cancer to become metastasized.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: January 27, 2009
    Assignee: The Regents of the University of California
    Inventors: Pamela L. Paris, Colin C. Collins
  • Men1 is a marker and therapeutic target for breast and prostate cancer
    Publication number: 20080125389
    Abstract: The present invention provides genomic markers for determining the presence or absence of breast cancer. The invention further demonstrates that inhibition of MEN1 reduces breast or prostate cancer proliferation, thereby demonstrating that inhibition of MEN1 activity or expression can be used to reduce breast cancer or prostate cancer proliferation in an individual in need thereof.
    Type: Application
    Filed: May 3, 2007
    Publication date: May 29, 2008
    Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIA Office of Technology Transfer
    Inventors: Pamela L. Paris, Colin C. Collins